Literature DB >> 30982817

[Snapshot evaluation of heart failure in Turkey: Baseline characteristics of SELFIE-TR].

Mehmet Birhan Yılmaz1, Ahmet Çelik2, Yüksel Çavuşoğlu3, Lütfü Bekar4, Ersel Onrat5, Mehmet Eren6, Merih Kutlu7, Kenan Yalta8, Ahmet Temizhan9, Barış Kılıçaslan10, Hasan Güngör11, Mahmut Açıkel9, Mesut Demir12, Ramazan Akdemir13, Mehdi Zoghi14, Lale Tokgözoğlu15.   

Abstract

OBJECTIVE: Heart failure (HF) is an important health issue of the 21st century and the prevalence in Turkey has been reported as 2.9%. A national profile, frequency data, characteristics of different phenotypes, and risk factors have not yet been well established. The Snapshot Evaluation of Heart Failure Patients in Turkey (SELFIE-TR) was an analysis of a representative sample of HF patients from Turkey.
METHODS: A total of 23 centers with at least 2 cardiologists from the 12 NUTS-1 regions of Turkey were invited to participate in the research. The contributing centers shared the data of a consecutive enrollment of HF patients, as confirmed by an investigator, on a pre-selected day of each week for the month of October or November of 2015.
RESULTS: The mean age of the entire cohort was 63.3+-13.3 years (male/female ratio: 751/303, 71.3%/28.7%). There were 712 acute HF patients and 342 chronic HF patients. The total number of HF patients with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction, and heart failure with preserved ejection fraction was 801 (75%), 176 (16.7%), and 77 (7.3%), respectively. The patients with chronic HF were younger than those with acute HF (61.1+-13.3 years vs 67.9+-12.1 years; p<0.001). Among the whole cohort, hypertension was observed in 46%, diabetes mellitus was present in 27.5%, chronic obstructive pulmonary disease was present in 12.8%, and previous myocardial infarction was noted in 45.2%. In patients with HFrEF, the use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, a beta blocker, or a mineralocorticoid receptor antagonist was noted in 74.7%, 89.7%, and 60.9%, respectively.
CONCLUSION: The SELFIE-TR findings provide important insight, since it is the first study to make a snapshot of HF patients in our country. These data may help to create standardized prevention and treatment strategies.

Entities:  

Mesh:

Year:  2019        PMID: 30982817     DOI: 10.5543/tkda.2019.66877

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  3 in total

1.  Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality.

Authors:  Mehmet Birhan Yılmaz; Emrah Aksakal; Uğur Aksu; Hakan Altay; Yıldırım Nesligül; Ahmet Çelik; Mehmet Ata Akil; Lütfü Bekar; Mustafa Gökhan Vural; Rengin Çetin Güvenç; Savaş Özer; Dilek Ural; Yüksel Çavuşoğlu; Lale Tokgözoğlu
Journal:  Anatol J Cardiol       Date:  2020-02       Impact factor: 1.596

2.  Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study.

Authors:  Umut Kocabaş; Tarık Kıvrak; Gülsüm Meral Yılmaz Öztekin; Veysel Ozan Tanık; Ibrahim Halil Özdemir; Ersin Kaya; Elif Ilkay Yüce; Fulya Avcı Demir; Mustafa Doğduş; Meltem Altınsoy; Songül Üstündağ; Ferhat Özyurtlu; Uğur Karagöz; Alper Karakuş; Örsan Deniz Urgun; Ümit Yaşar Sinan; Inan Mutlu; Taner Şen; Mehmet Ali Astarcıoğlu; Mustafa Kınık; Özge Özden Tok; Begüm Uygur; Mehtap Yeni; Bahadır Alan; Onur Dalgıç; Çağla Sarıtürk; Hakan Altay; Seçkin Pehlivanoğlu
Journal:  Anatol J Cardiol       Date:  2020-07       Impact factor: 1.596

3.  Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II.

Authors:  Duygu Koçyiğit; Nedim Umutay Sarıgül; Ali Timuçin Altın; Serkan Çay; Veli Polat; Serkan Saygı; Hasan Ali Gümrükçüoğlu; Kani Gemici; Barış İkitimur; Ahmet Akyol; Ahmet Kaya Bilge; İbrahim Başarıcı; Emin Evren Özcan; Mesut Demir; Hasan Kutsi Kabul; Ender Ornek; Camilla Normand; Cecilia Linde; Kenneth Dickstein
Journal:  Anatol J Cardiol       Date:  2020-12       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.